Interestingly, earlier studies have demonstrated that PPARγ is a potent regulator of inflammation [21], [28] and in vivo treatment with PPARγ agonists reduces clinical symptoms of MS, Alzheimer's disease, spinal cord injury, and stroke in animal models [29]–[31]. This evidence concerns the gene PPARG and early-onset autosomal dominant Alzheimer disease.